Health Catalyst, Inc. (HCAT) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. Health Catalyst, Inc. is a leading provider of data and analytics technology and services to healthcare organizations. The company operates through two segments: Technology (cloud-based data platform and analytics applications) and Professional Services (analytics, implementation, and advisory services). The reporting period reflects ongoing strategic shifts, including the migration of clients to the "Health Catalyst Ignite" platform and significant restructuring initiatives.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 6M 2025 | YTD 6M 2024 |
|---|---|---|---|---|
| Total Revenue | $80,721 | $75,902 | $160,134 | $150,625 |
| Net Loss | $(40,978) | $(13,516) | $(64,720) | $(34,103) |
| Adjusted EBITDA | $9,344 | $7,522 | $15,623 | $10,899 |
| Cash & Equivalents | $50,712 | $249,645 (Dec '24) | $50,712 | $201,895 (Jun '24) |
| Short-term Investments | $46,626 | $142,355 (Dec '24) | $46,626 | $142,355 (Dec '24) |
| Total Debt (Principal) | $161,574 | $392,388 (Dec '24) | $161,574 | $392,388 (Dec '24) |
| Operating Cash Flow (6M) | $(8,717) | $11,878 | $(8,717) | $11,878 |
Note: Debt figures reflect the repayment of $230 million in Convertible Senior Notes in April 2025. Remaining debt consists of a term loan facility.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 6% year-over-year (YoY) for the quarter and 6% for the six-month period. Technology revenue grew 11% YoY in Q2, driven by new clients and contractual escalators, while Professional Services revenue declined slightly (1%) due to lower utilization rates.
- Goodwill Impairment: The company recorded a non-cash goodwill impairment charge of $28.8 million in Q2 2025. This was triggered by a decline in stock price, market capitalization, and a downward revision of future revenue forecasts. This charge significantly impacted the Net Loss.
- Debt Restructuring: In April 2025, the company fully repaid its $230 million Convertible Senior Notes using proceeds from a new credit agreement and cash on hand. The new credit facility (Silver Point Finance) provides up to $225 million, with $161.6 million outstanding as of June 30, 2025.
- Operating Expenses: General and Administrative (G&A) expenses decreased 42% YoY in Q2, primarily due to a $5.2 million decrease in the fair value of contingent consideration liabilities. Research and Development (R&D) expenses decreased 11% YoY due to workforce reductions.
- Liquidity: Cash and cash equivalents decreased significantly from $249.6 million at year-end 2024 to $50.7 million at June 30, 2025, largely due to debt repayments and operating cash outflows.
Guidance, Outlook, and Risks
- Macroeconomic Headwinds: Management cites high inflation, interest rates, and specifically the "One Big Beautiful Bill Act" (OBBBA) signed in July 2025, which projects nearly $1 trillion in Medicaid spending cuts over 10 years. This is expected to elongate sales cycles and reduce bookings.
- Platform Migration: The migration of clients from the legacy DOS platform to "Health Catalyst Ignite" is ongoing. While expected to improve margins long-term, it is currently creating near-term cost pressures and some clients are opting for price reductions during migration.
- Restructuring: The company executed a workforce reduction in Q1 2025 (approx. 4% of global workforce). A subsequent restructuring plan was announced in August 2025 (post-period), targeting an additional 9% reduction in Q3 2025, primarily in R&D and Sales/Marketing, with expected charges of at least $4.5 million.
- Acquisitions: The company acquired Upfront Healthcare Services in January 2025 ($80 million consideration). Revenue from this acquisition was not material in the first half of 2025.
- Risks: Key risks include the inability to compete effectively, failure to execute growth initiatives, client churn due to macroeconomic strain, and potential further goodwill impairment if stock price declines continue.
Investor Verification Checklist
- Goodwill Impairment Details: Verify the specific assumptions used in the quantitative impairment test (discount rates, revenue growth forecasts) to assess the risk of future impairments.
- Cash Burn Rate: Monitor the trajectory of operating cash flow given the significant drop in cash reserves to ~$50 million and the shift from positive to negative operating cash flow.
- Debt Covenants: Review the specific leverage ratios and minimum liquidity thresholds in the new Silver Point Finance credit agreement to ensure compliance given the current cash position.
- Migration Economics: Assess the long-term margin impact of the Ignite migration versus the short-term revenue reductions clients are demanding during the transition.
- Restructuring Execution: Track the actual costs and timeline of the August 2025 restructuring plan to verify the projected $4.5 million charge and subsequent expense reductions.